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Anogenital Distance: 
Defining “Normal”
In their letter to EHP, McEwen and Renner
(2006) dismissed the findings of Swan et al.
(2005), who reported a significant relation-
ship between a measure of anogenital dis-
tance (AGD) in boys and levels of phthalate
metabolites in their mothers’ urine during
pregnancy. AGD is a sexually dimorphic
index that, on average, is twice as great in
males as in females, so it serves as a marker
of proper male development. McEwen and
Renner based their argument on an idio-
syncratic form of logic. They asserted that
All male infants evaluated in the study appeared
normal … there is no evidence for potential
adverse effect in the test population. … no conclu-
sion can be drawn whether the reported values are
normal or abnormal. The range of AGD values …
likely represents typical biologic variation that
would be expected to occur among normal study
subjects.
McEwen and Renner seem to be wholly
unfamiliar with the meaning of a modest or
even a slight shift in the mean of an index
that reflects the distribution of susceptibility
in a population. I have pointed out (Weiss
1988) that even a 5-point (5%) reduction
in mean intelligence quotient in a popula-
tion of 100 million increases the number of
individuals classified as retarded from
6 million to 9.4 million. It is this kind of
relationship that eventually prompted the
Centers for Disease Control and
Prevention (CDC) to lower its definition of
elevated lead risk levels in blood, set at
40 µg/dL in 1970, to 10 µg/dL in 1991
(CDC 1991). Bellinger (2006) put it this
way: 
A small change in the mean signals predictable
accompanying changes in the proportions of
individuals in the source population who fall into
the tails of the distribution, where individuals
who meet diagnostic criteria are found. Thus, the
importance of a shift in group mean lies not in
what it indicates about the average change among
members of the study sample, but what it implies
about the changes in the tails of the distribution
in the population from which the study sample
was drawn.
He noted, based on Rose (1981), that in a
population with a prevalence of clinically
defined hypertension of 15%, a 5-mm
reduction in mean systolic blood pressure
would result in a 33% decrease in prevalence
(Bellinger 2006). Epidemiologists recognize
that a slight decrease in mean blood pressure
in a population is translated into a major
decrease in the incidence of serious cardio-
vascular events such as heart attacks. 
We already know that shortened AGD
at birth is one element, the leading edge, as
it were, of the “phthalate syndrome” in rats,
which is marked by testicular pathology,
reduced spermatogenesis, hypospadias, and
cryptorchidism, a compilation of signs indi-
cating disordered male development that
Sharpe (2001) and others have noted to be
on the increase in industrialized nations. An
almost imperceptible shift to a lower mean
AGD in the human male would foreshadow
a heightened prevalence of reproductive
system dysfunction. Is that the connection
now emerging in the clinic?
If McEwen and Renner’s (2006) criteria
for “normal” were to govern the way in
which we define the health risks of lead
exposure, we would be basing our criteria
on the number of children brought into
hospital emergency rooms with lead poison-
ing rather than on the threats it poses to
their neurobehavioral development. No
parent, and no community, would tolerate
such a definition these days. 
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Anogenital Distance: Bailey
and Renner Respond
In his letter, Weiss misrepresents the argu-
ments presented in our letter (McEwen and
Renner 2006) regarding the study of Swan
et al. (2005). We pointed out that a value for
“normal” anogenital distance (AGD) is not
known and that without this information,
“abnormal” AGD values cannot be deter-
mined. Swan et al. (2005) measured AGD in
a limited number of subjects (134 boys) who
varied widely in age, height, and weight.
This small sample size is inadequate to deter-
mine a normal AGD value, and there are no
historical control data for AGD in male
human infants using a definition of AGD
comparable to the one used by Swan et al.
Although the significance of AGD val-
ues in humans, if any, is unknown, it is clear
that a meaningful study with AGD as the
end point of interest requires knowledge of
normal values as a prerequisite. Further, the
lack of knowledge of normal AGD values is
only one of the significant limitations of the
study by Swan et al. (2005); others were
identified in our previous letter (McEwen
and Renner 2006).
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Mercury from Fish Does Not
Reduce Children’s IQs
Trasande et al. (2005) concluded that pre-
natal methylmercury (MeHg) exposure is
reducing children’s IQs (intelligence quo-
tients), costing $8.7 billion/year. They
achieved this high estimate a) by assuming
that IQ reductions occur at MeHg exposures
near or even below the 5.8 µg/L reference
dose (RfD), although there is no evidence for
IQ reductions even at much higher expo-
sures; and b) by overstating by nearly a factor
of three the fraction of newborns with
MeHg exceeding the RfD. I believe that
their analysis is flawed, invalid, and not
appropriate as an input to policy decisions. 
Trasande et al. (2005) assumed that 10%
of newborns are exposed prenatally to MeHg
exceeding the RfD. However, the appropri-
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ate value is 3.6%. Trasande et al. made two
errors. First, they used a lower RfD than
5.8 µg/L, based on the observed enrichment
of MeHg in umbilical cord blood relative to
maternal blood. However, the current RfD
already accounts explicitly for this enrich-
ment through an uncertainty factor of 3.15
applied to the benchmark dose lower limit
[U.S. Environmental Protection Agency
(EPA) 2001]. Second, they assumed that
women 16–49 years of age measured during
1999–2000 accurately represented MeHg
levels in pregnant women (Mahaffey et al.
2004). National Health and Nutrition
Examination Survey (NHANES) data col-
lected during 1999–2002 (Jones et al. 2004),
available before Trasande et al. (2005) sub-
mitted their manuscript, show the 95th per-
centile MeHg level for pregnant women to
be 32% below Trasande et al.’s value.
If any MeHg exposure above the RfD
reduced IQ, there would still be cause for
concern. However, there is no evidence for
IQ reductions even at exposures several
times the RfD. 
Previous studies in the Seychelles Islands
(Myers et al. 2003) and New Zealand
(Crump et al. 1998) did not find IQ reduc-
tions at any MeHg exposure. A study in the
Faroe Islands (Grandjean et al. 1999) did
not measure IQ. Many children in these
studies had prenatal MeHg exposures
exceeding 10 times the RfD. The claim of
IQ reductions in Americans is even weaker
because Americans’ MeHg exposures are far
lower. Of 629 pregnant women measured
by NHANES, the highest exposure was
3.7 times the RfD (Centers for Disease
Control and Prevention 2005). Among
those exceeding the RfD, 75% were below
twice the RfD. 
Trasande et al. (2005) cited results from
the Faroe Islands (Grandjean et al. 1999) to
claim IQ reductions, but this study is less
compelling than the Seychelles study (Myers
et al. 2003b) for assessing Americans’ risks:
a) the Seychellois are exposed to MeHg
through ocean fish, similar to Americans,
whereas the Faroese are exposed through
whale meat (Myers et al. 2003b); b) the
Seychellois are ethnically diverse, but the
Faroese are homogeneously Scandinavian
(Rice et al. 2003); and c) the Seychelles study
used hair MeHg to measure exposure, and
the Faroes study used cord blood. Hair
MeHg has been calibrated with fetal brain
levels, but cord blood has not (Cernichiari
et al. 1995; Myers et al. 2003a). 
Despite the advantages of the Seychelles
study, Trasande et al. (2005) dismissed it,
claiming that the National Research Council
(NRC 2000) “opined that the most credible
of the three prospective epidemiologic stud-
ies was the Faroe Islands investigation.” In
reality, referring to all three studies, the NRC
(2000) concluded that “each of these studies
was well designed and carefully conducted.”
Nevertheless, the NRC “concluded that a
well-designed study with positive effects pro-
vides the most appropriate public-health
basis for the RfD.” The NRC thus excluded
the Seychelles study not because of the qual-
ity of the study but because the study found
that MeHg did not cause any harm. 
Trasande et al. (2005) also made other
errors:
• They claimed that the New Zealand study
reported IQ reductions, citing Kjellstrom
et al. (1986, 1989). However, they omitted
Crump et al.’s (1998) reanalysis, co-
authored with Kjellstrom, which superseded
previous reports and found no IQ reduction. 
• They claimed that the Seychelles study had
only half the statistical power of the Faroes
study. The studies actually have similar
power (Myers et al. 2003; NRC 2000). 
• They claimd the NRC concluded that
MeHg reduces IQs even at exposures lower
than the RfD. However, the NAS cautioned
that the cohort studies were incapable of
assessing effects of exposures near the RfD,
because hardly any children had such low
MeHg exposures (NRC 2000).
The weight of the evidence indicates
that MeHg, even at exposures substantially
greater than the highest U.S. levels, does
not reduce children’s IQ. The evidence
against IQ reductions is particularly strong
for MeHg exposures from fish. 
Trasande et al. (2005) relied on mis-
taken assumptions regarding exposures to
and effects of MeHg, and misinterpreted or
omitted contrary evidence. Therefore, I
consider their analysis to be fundamentally
flawed and invalid. 
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Children’s IQs: Trasande et al.
Respond
Schwartz makes a number of claims regard-
ing our methodology (Trasande et al. 2005)
that are inaccurate and based on a selective
reading of the literature.
In our article (Trasande et al. 2005), we
estimated the health and economic conse-
quences of prenatal methylmercury (MeHg)
exposure in the 2000 U.S. birth cohort. Our
major findings were that at least 316,588
children in that birth cohort suffered IQ
(intelligence quotient) loss of
0.2–24.4 points as a result of MeHg toxicity
sustained in utero. This loss of intelligence
causes diminished economic productivity
that will persist, and this lost productivity is
the major monetary consequence of
methylmercury toxicity. We used the most
up-to-date publicly available data on mer-
cury exposures and health outcomes,
applied a risk assessment approach devel-
oped by the National Research Council
(NRC 1994), and made conservative
assumptions throughout.
To compute decrements in IQ that
resulted from prenatal mercury exposures,
we used data from Mahaffey et al. (2004) on
percentages of women of childbearing age in
1999–2000 with mercury concentrations
≥ 3.5, 4.84, 5.8, 7.13, and 15.0 µg/L. These
A 400 VOLUME 114 | NUMBER 7 | July 2006 • Environmental Health Perspectivesdata most closely reflect exposure to women
in the years 1999–2000, when toxicity to
the developing brains of children in the
2000 birth cohort would have occurred. We
then applied logarithmic and linear models
to these data, and we calculated a range of
IQ decrements for each subpopulation born
with a cord blood mercury concentration
> 5.8 µg/L. To assess a range of possible out-
comes, we conducted a sensitivity analysis in
which we applied a range of IQ decrements
for each increase in mercury concentration.
We described our methods in great detail
(Trasande et al. 2005). Through this series
of calculations, we generated upper and
lower ranges of possible IQ decrements for
each subpopulation among the most highly
exposed children in the 2000 U.S. birth
cohort.
In his letter, Schwartz asserts that it is
impossible to impute effects on children’s
intelligence of prenatal exposures to mercury
near the U.S. Environmental Protection
Agency’s (EPA) reference dose (RfD). In
proffering this assertion, he appears to
ignore a recent meta-analysis of the three
studies that confirmed a dose–response rela-
tionship between low-level prenatal MeHg
exposure and IQ (Cohen et al. 2005). A
recent U.S. cohort study has also detected
decrements in visual recognition memory
among children exposed prenatally to
MeHg (Oken et al. 2005).
Schwartz suggests that we should have
used the U.S. EPA benchmark dose level
(BMDL) of 58 µg/L as a cutoff. He appar-
ently assumes that no injury occurs to fetal
brains from exposure to MeHg below that
level. That approach does not reflect bio-
logic or epidemiologic reality. We based our
selection of 5.8 µg/L as a no adverse effect
level on the epidemiologic evidence, not on
the U.S. EPA’s regulatory documents
(Budtz-Jorgensen et al. 2004; Grandjean
et al. 1999; Kjellstrom et al. 1986, 1989).
We relied especially upon the NRC’s report
on prenatal exposure to MeHg (NRC
2000), which concluded that the likelihood
of subnormal scores on neuro-
developmental tests increased as cord blood
mercury concentrations increased from lev-
els as low as 5 µg/L. Methylmercury expo-
sure has also been associated with persistent
delays in peak I–III brainstem-evoked
potentials at cord blood levels < 5 µg/L
(Murata et al. 2004).
Schwartz misrepresents Crump et al.’s
findings (1998), stating that they “super-
seded previous reports and found no IQ
reduction.” In fact, the NRC (2000) stated
that Crump et al. 
reported nonsignificant results from a regression
analysis on all the children in the New Zealand
cohort, but [that these results became significant]
after omission of a single child whose mother’s hair
Hg concentration was 86 ppm (4 times higher than
that of the next highest exposure level in the study).
Schwartz misrepresents our characteri-
zation of the Seychelles Islands study
(Landrigan and Goldman 2003; Myers et al.
2003), accusing us of stating that it had half
the statistical power of the Faroe Islands
study (Grandjean et al. 1999). In actuality,
we stated that the Seychelles study “had only
50% statistical power to detect the effects
observed in the Faroes” (Trasande et al.
2005). Schwartz asserts that the NRC’s
choice not to apply the Seychelles data in
setting an RfD represents equivocation
about the health effects of MeHg. In actual-
ity, the NRC came to the same conclusion
as we did: “[t]he weight of the evidence of
developmental neurotoxic effects from
exposure to MeHg is strong” (NRC 2000).
Recent work (Trasande et al. 2006) sug-
gests that our calculation of the economic
costs (Trasande et al. 2005) may, in fact, be
an underestimate. The new study indicates
that downward shifts in IQ are also associ-
ated with thousands of excess cases of mental
retardation (defined as IQ < 70) in the
United States each year. Care of these chil-
dren is associated with needs for health care,
special education, and other services that
impose a great burden on society.
All of these adverse consequences can be
prevented by prevention of prenatal exposure
to MeHg.
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ERRATUM
A line of text was inadvertently
omitted from the June 2006
Innovations article (“Plant vs.
Pathogen: Enlisting Tobacco in
the Fight Against Anthrax,”
EHP 114:A364–A367 [2006]).
The last sentence on page A365
should read: “The current
anthrax vaccine works on this
very principle by introducing
nonvirulent PA into the body so
antibodies are created.” EHP
regrets the error.